Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Iryna Kriachok"'
Autor:
Paolo Ghia, Andrzej Pluta, Małgorzata Wach, Daniel Lysak, Martin Šimkovič, Iryna Kriachok, Árpád Illés, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Ganna Usenko, Min Hui Wang, Ting Yu, Wojciech Jurczak
Publikováno v:
HemaSphere, Vol 6, Iss 12, p e801 (2022)
Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia (CLL). ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator’s choice of idelalisib plus rituximab (IdR) or bendamustine
Externí odkaz:
https://doaj.org/article/8861f967d3964d909ede74df166018f2
Autor:
Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin, Tuphan K. Dolai, Dinesh K. Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Michele Cavo, Yi Chai, Jacqueline Jeha, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson, Sebastian Grosicki
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Abstract Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in t
Externí odkaz:
https://doaj.org/article/20b9da9076424d1f8dc1d21eef7bc3c4
Autor:
Matthew S. Davids, Asher Chanan-Khan, Boyd Mudenda, Larysa Nogaieva, Iryna Kriachok, Hanna Usenko, Vladimir Ivanov, Olena Kyselova, Tetiana Perekhrestenko, Ivan Muzhychuk, Alexander Myasnikov, Zvenyslava Maslyak, Andrew Proidakov, Olga Uspenskaya, Elena Borisenkova, Paula Marlton, Tanya Siddiqi, Allison Winter, Tamila Lysa, Bulat Bakirov, Lei Fu, Zi Chen, Min Yu, Mingyu Li, Laura Glass, Mohammad Ahmad, Olena Karpenko, Iurii Osipov, Asit De, Ben Paudyal, Hengbang Wang, Robert Winkler, Nashat Gabrail, Vinod Ganju, Tatiana S. Konstantinova, Olga S. Samoylova, Dajun Yang, Yifan Zhai
Publikováno v:
Blood. 140:2326-2328
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43fec5f75e1286dfcef8a36c5c7cbaa6
https://doi.org/10.1182/blood-2022-160386
https://doi.org/10.1182/blood-2022-160386
Autor:
Iryna Kriachok, Yana Stepanishyna, Tetiana Skrypets, Nazar Shokun, Arina Martynchyk, Iryna Tytorenko, Olena Aleksik, Mykhailo Krotevych, Martina Manni, Massimo Federico
Publikováno v:
Hematological oncologyREFERENCES.
The Ukrainian Lymphoma Registry (ULR) was established in 2019 with the aim of monitoring the quality of diagnosis, staging, and treatment of lymphoma in Ukraine. Between September 2019 and October 2021, 546 patients with newly diagnosed lymphoma were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::056b5197b0bc065deec45da2391dcaff
https://pubmed.ncbi.nlm.nih.gov/35932211
https://pubmed.ncbi.nlm.nih.gov/35932211
Autor:
Radhakrishnan Ramchandren, Mieczyslaw Komarnicki, Akash Nahar, Valeria Buccheri, Patricia Marinello, John Kuruvilla, Iara Goncalves, Andrew M. McDonald, Nathalie A. Johnson, Muhit Ozcan, Michael Dickinson, Guilherme Fleury Perini, Iryna Kriachok, Ying Zhu, Neta Goldschmidt, Pier Luigi Zinzani, Armando Santoro, Ewa Paszkiewicz-Kozik, José Salvador Rodrigues de Oliveira, Robin Gasiorowski, Keynote investigators, Laura Fogliatto, Naohiro Sekiguchi
Publikováno v:
The Lancet Oncology. 22:512-524
Summary Background PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pemb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c03c688568fb66a265532f665972c78d
https://doi.org/10.1016/s1470-2045(21)00005-x
https://doi.org/10.1016/s1470-2045(21)00005-x
Publikováno v:
The Peripheral T-Cell Lymphomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18810098855103974aec146452f8aed8
https://doi.org/10.1002/9781119671336.ch26
https://doi.org/10.1002/9781119671336.ch26
Autor:
Yana Stepanishyna, Iryna Kriachok, Nazar Shokun, Nataliia Shapovalenko, Anisiia Luchkiv, Tetiana Skrypets, Martina Manni, Massimo Federico
Publikováno v:
Blood. 140:9525-9525
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::988374e4d8d61f3730c0d7b3a6259b1f
https://doi.org/10.1182/blood-2022-166484
https://doi.org/10.1182/blood-2022-166484
Autor:
Wojciech Jurczak, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Martin Simkovic, Iryna Kriachok, Árpád Illés, Javier De La Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric Joseph Avery, Jae Hoon Lee, Ganna Usenko, Min Hui Wang, Ting Yu, Paolo Ghia
Publikováno v:
Journal of Clinical Oncology. 40:7538-7538
7538 Background: Acalabrutinib (acala) is a next-generation, highly selective, covalent Bruton tyrosine kinase (BTK) inhibitor approved for patients (pts) with chronic lymphocytic leukemia (CLL). In the primary analysis of ASCEND (median follow-up 16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd634fd4fa162f96c5959e82be18598b
https://doi.org/10.1200/jco.2022.40.16_suppl.7538
https://doi.org/10.1200/jco.2022.40.16_suppl.7538
Autor:
Ashraf Badros, Nizar J. Bahlis, Roman Hájek, Larry D. Anderson, Vadim A Doronin, Meletios A. Dimopoulos, Jacqueline Jeha, Halyna Pylypenko, Jatin P. Shah, Reuben Benjamin, Sebastian Grosicki, Maria Gavriatopoulou, Dinesh Kumar Sinha, Xavier Leleu, Thierry Facon, Tuphan Kanti Dolai, Michele Cavo, Don A. Stevens, Moshe Yair Levy, Iryna Kriachok, Sundar Jagannath, L. Pour, Paul G. Richardson, Holger W. Auner, Maria V. Mateos, Sharon Shacham, Sosana Delimpasi, Hang Quach, Yi Chai, Mamta Garg, Michael Kauffman, Ivan Spicka, Maryana Simonova, Philippe Moreau, Christopher P. Venner, Ganna Usenko, Melina Arazy
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf7cc61cc2d359ff206c62213e34e08
http://hdl.handle.net/10044/1/89189
http://hdl.handle.net/10044/1/89189
Autor:
Michele Cavo, Sundar Jagannath, Reuben Benjamin, Ganna Usenko, Sebastian Grosicki, Maryana Simonova, Xavier Leleu, Larry D. Anderson, Moshe Yair Levy, Hang Quach, Sosana Delimpasi, Ivan Spicka, Mamta Garg, Thomas Illmer, L. Pour, Paul G. Richardson, Nizar J. Bahlis, Hailin Yu, Jatin P. Shah, Shijie Tang, Christopher P. Venner, Hoyee Leong, Meletios A. Dimopoulos, Larysa Sanchez, Jennifer L. Beaumont, Don A. Stevens, Sharon Shacham, Iryna Kriachok, Thierry Facon, Yi Chai, Michael Kauffman, Holger W. Auner, Roman Hájek, Dinesh Kumar Sinha, Xiwen Ma, Stacie Hudgens
Publikováno v:
E386
E383
E383
NA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdcafd469edafb4d03d8289681092dba
http://hdl.handle.net/11585/865053
http://hdl.handle.net/11585/865053